Our client wanted to broaden access and funding for their reproduction biosimilar in the UK. However...
Read moreOur client wanted to gain a better understanding of current and forthcoming policy measures affectin...
Read moreDevelopment and submission of payer communication materials and pricing and reimbursement dossiers f...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThe first adalimumab (branded Humira) biosimilar, Amjevita, has been launched in the US by pharmaceu...
Read moreOur client asked Remap Consulting to support them in the development of a peer-reviewed publication ...
Read moreDevelopment of local market access plans that could be used by EU affiliates, who had not previously...
Read moreWe discuss the advantages and disadvantages of using international reference pricing for consistent ...
Read moreThe pricing dynamics of biosimilars, depends on the type of biosimilar, its indication and the chann...
Read moreThe short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...
Read more